Open Access
Subscription or Fee Access
Structure and Origin Insight of Recent Corona Virus with Ongoing Therapeutic Approach
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is highly transmissible zoonotic virus that was initially reported in late 2019 in Wuhan, China. Presently, it has infected approximately 1.5 million person and responsible for more than 0.1 million death across the world. It is likely evolved from bats and pangolin and genetically different from SARS-CoV-1, responsible for SARS disease. In present review, we have discussed the recent finding of its origin from bats and pangolin, its phylogenetic comparison from other coronavirus and ongoing therapeutic approaches against the fight of SARS-CoV-2.
Keywords
References
Cui J, Li F, Shi Z-L. Origin and Evolution of Pathogenic Coronaviruses. Nat Rev Microbiol. 2019; 17(3): 181–192p.
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281–286p.
Organization WH. Novel Coronavirus ( 2019-nCoV): Situation Report. 2020; 3.
Organization. WH. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is Suspected: Interim Guidance, 13 March 2020. World Health Organization; 2020.
Zhang Y-Z, Holmes EC. A Genomic Perspective on the Origin and Emergence of Sars-Cov-2. Cell. 2020; 181(2): 223–227p.
Hamming I, et al. Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis. J Pathol: A Journal of the Pathological Society of Great Britain and Ireland. 2004; 203(2): 631–637p.
Bodiga VL, Bodiga S. Renin Angiotensin System in Cognitive Function and Dementia. Asian Journal of Neuroscience. 2013; 2013: 1–18p.
Matsuyama S, et al. Enhanced Isolation of SARS-CoV-2 by TMPRSS2-Expressing Cells. Proc Natl Acad Sci. 2020; 117(13): 7001–7003p.
Báez-Santos YM, John SES, Mesecar AD. The SARS-Coronavirus Papain-Like Protease: Structure, Function and Inhibition by Designed Antiviral Compounds. Antiviral Res. 2015; 115: 21–38p.
Shereen MA, et al. COVID-19 Infection: Origin, Transmission, and Characteristics of Human Coronaviruses. J Adv Res. 2020; 24: 91–98p.
Yan R, et al. Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2. Science. 2020; 367(6485): 1444–1448p.
Andersen KG, et al. The Proximal Origin of SARS-CoV-2. Nature Medicine. 2020; 1–3p.
Coutard B, et al. The Spike Glycoprotein of the New Coronavirus 2019-nCoV Contains a Furin-Like Cleavage Site Absent in CoV of the Same Clade. Antiviral Res. 2020; 176: 104742p.
Follis KE, York J, Nunberg JH. Furin Cleavage of the SARS Coronavirus Spike Glycoprotein Enhances Cell–Cell Fusion but does not Affect Virion Entry. Virology. 2006; 350(2): 358–369p.
Menachery VD, et al. Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. J Virol. 2020; 94(5): e01774–19.
Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr Biol. 2020; 30(8): 1578p.
Zhou P, et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature. 2020; 579(7798): 270–273p.
Tang X, et al. On the Origin and Continuing Evolution of SARS-CoV-2. Natl Sci Rev. 2020; nwaa036.
Li X, et al. Evolutionary History, Potential Intermediate Animal Host, and Cross‐Species Analyses of SARS‐CoV‐2. J Med Virol. 2020; 92(6): 602–611p.
Velavan TP, Meyer CG. The COVID-19 Epidemic. Trop Med Int Health. 2020; 25(3): 278–280p.
Sahu KK, Mishra AK, Lal A. Comprehensive Update on Current Outbreak of Novel Coronavirus Infection (2019-nCoV). Ann Transl Med. 2020; 8(6): 393p.
Li G, De Clercq E. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV). Nature Publishing Group, Nat Rev Drug Discov. 2020; 19(3): 149–150p.
Shiraki K, Daikoku T. Favipiravir, an Anti-Influenza Drug against Life-Threatening RNA Virus Infections. Pharmacol Ther. 2020; 209: 107512p.
Guo D. Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases. Virol Sin. 2020; 35(3): 1–3p.
Zumla A, et al. Coronaviruses: Drug Discovery and Therapeutic Options. Nat Rev Drug Discov. 2016; 15(5): 327–347p.
Senanayake SL. Drug Repurposing Strategies for COVID-19. Future Science, Future Drug Dicov. 2020; 2(2): 1–3p.
Wang D, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069p.
Rosa SGV, Santos WC. Clinical Trials on Drug Repositioning for COVID-19 Treatment. Rev Panam Salud Pública. 2020; 44: e40p.
Hoffmann M, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280p.
Owens B. Excitement around Hydroxychloroquine for Treating COVID-19 Causes Challenges for Rheumatology. Lancet Rheumatol. 2020; 2(5): e257p.
Gautret P, et al. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. Int J Antimicrob Agents. 2020; 56(1): 105949p.
Chen L, et al. Convalescent Plasma as a Potential Therapy for COVID-19. Lancet Infect Dis. 2020; 20(4): 398–400p.
Organization WH. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance, 28 January 2020. World Health Organization; 2020.
Casadevall A, Pirofski L-A. The Convalescent Sera Option for Containing COVID-19. The J Clin Investig. 2020; 130(4): 1545–1548p.
Refbacks
- There are currently no refbacks.